High-dose rituximab and anti-MAG-associated polyneuropathy.
case_series · Level IV
Where this comes from
- Record sourced from PubMed, PMID 16534115.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Rituximab has been administered successfully in patients with polyneuropathy associated with antibodies to myelin-associated glycoprotein (anti-MAG). The authors present a follow-up study with high-dose rituximab. Increase of rituximab from 375 mg/m2 to a dose of 750 mg/m2 was well tolerated and led to clinical improvement in four of eight patients, along with improvement of nerve conduction velocities and a reduction of anti-MAG antibody titers.
Medical subject headings
- Antibodies, Monoclonal
- Immunologic Factors
- Myelin-Associated Glycoprotein
- Polyneuropathies